For decades, pharmaceutical pricing strategy has operated in two largely separate worlds. U.S. teams focused on net pricing, rebates, and channel management. Ex-US teams managed list prices, IRP networks, and launch sequencing. These disciplines ran in parallel, occasionally intersecting but rarely integrated.

That era is ending. With MFN, the GENEROUS Medicaid model, and the proposed GLOBE and GUARD models, international prices now directly shape U.S. Medicare and Medicaid outcomes. Crucially, these policies are designed as multi-year models, meaning early pricing and disclosure decisions can shape exposure well beyond the initial launch window.

↔ Drag the slider to compare the old pricing silos with the new integrated global pricing model.

The implication is clear: pricing strategy can no longer be siloed. Decisions made in one market now have direct consequences in others. Understanding these dynamics matters not just for manufacturers, but for policymakers, payers, and anyone seeking to anticipate how global drug pricing will evolve. This article explores what that means—first for U.S. strategy, then for ex-US strategy, and finally for how to bring them together.

Part I: Strategic Considerations for the U.S. Market

Start with Channel Exposure

The strategic relevance of MFN, GENEROUS, GLOBE, or GUARD depends less on policy design than on where value sits. Products with similar prices and international footprints may require very different strategies purely because their U.S. channel exposure differs across Medicaid, Medicare Part B, Medicare Part D, and commercial channels.

The Strategic Implications

MFN set the template—the first policy to clearly link U.S. prices to international benchmarks and force a fundamental trade-off between U.S. net revenues and long-term global pricing integrity.

GENEROUS extends this logic into Medicaid through a voluntary framework. While participation is optional, the implications are not. A Medicaid MFN price can quickly become a reference point, shaping commercial negotiations, launch sequencing, and global price corridors. Read our full GENEROUS explainer →

GLOBE and GUARD bring similar thinking into Medicare, but with an important distinction:

• GLOBE (Part B) introduces an explicit international benchmark that adjusts for economic differences across countries and reduces flexibility over time. The downside is clear and predictable unless manufacturers choose to submit international net prices.
• GUARD (Part D) embeds international benchmarking within the inflation rebate calculation. While the benchmark construction mirrors GLOBE, CMS does not fully specify how the international benchmark will translate into realised inflation rebate exposure over time. As a result, manufacturers face uncertainty in economic impact unless they actively intervene through benchmark submission and pricing strategy. This rebate-based uncertainty is inherent to the model and persists throughout its duration.

The distinction matters: GLOBE presents a known trade-off; GUARD presents uncertainty that requires proactive management.

Part II: Rethinking Ex-US Strategy

International Prices Travel Further

What has changed is not the existence of international reference pricing, but the extent to which U.S. policy now pulls international prices back into Medicare and Medicaid outcomes. A discounted or constrained launch in a single country can cascade through IRP networks, compress global price corridors, and reappear—directly or indirectly—in U.S. benchmarking and rebate exposure. Because U.S. benchmarks and rebates are applied over multiple years, modest price differences in early ex-US launches can translate into materially larger U.S. exposure over time.

Managing the Net vs List Asymmetry

U.S. policies increasingly focus on net pricing—incorporating rebates, discounts, and inflation penalties. By contrast, international reference pricing systems continue to rely largely on list prices. This asymmetry matters.

Launch Sequencing as Strategy

Launch sequencing has always carried strategic weight for managing IRP networks and global price corridors. Direct U.S. exposure adds a new dimension, making critical questions even more pressing:

• Where to launch first, and what that signals to the market
• Which markets can tolerate lower list prices without destabilising the global price corridor
• Where delayed or managed entry may better protect long-term value

Early list prices in one market can constrain pricing flexibility elsewhere, shaping both IRP spillovers and U.S. exposure under GLOBE and GUARD. These early decisions can shape future Medicare rebate exposure well beyond the first years on market.

The Return of the No-Launch Question

An uncomfortable implication of this shift is the renewed relevance of the no-launch question. For some high-value products with significant U.S. exposure, launching at a low list price in a small market may create more downside—via IRP and U.S. benchmarking—than upside through local revenue or access.

Part III: Building a Unified Approach

Integrated Modelling

In this environment, effective decision-making requires integrated analysis that connects:

The objective is not perfect prediction, but confidence in decision-making.

Portfolio and Lifecycle Thinking

No single response works across an entire portfolio. The right strategy depends on lifecycle stage:

Portfolio-Level Governance

These decisions require coordinated global governance with clear principles around:

• Acceptable global price corridors
• Conditions for delayed or selective launch
• Alignment mechanisms between U.S. and ex-US teams

Governance becomes a strategic capability and the infrastructure that enables coherent global decision-making.